|
|
News Breaks | | | | March 8, 2013 | | 08:37 EDT |  | PRAN | Prana provides further detail on presentation of new PBT2 data
Prana Biotechnology, following on from its announcement released on March 4 and at the request of the Australian Securities Exchange, provided further detail in respect to the presentation of the new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment. The data was generated in an animal model that overproduces the tau protein giving rise to 'tangle like' inclusions similar to those which cause neuronal death in Alzheimer's disease, the company said. Prana stated: "Importantly, whilst the anti-aggregation effects of PBT2 on Abeta have been well documented, these results were generated in a model which is independent of the presence of Abeta, indicating that PBT2 has the ability to prevent neuronal damage via multiple metal mediated pathways, including Abeta and tau aggregation." The data is being presented by Prana scientist Associate Professor Paul Adlard on March 9 in his presentation entitled, "Metal Chaperones are novel therapeutic agents for tauopathy". Administration of PBT2 resulted in significant improvement in performance in the Y maze, a significant reduction in the number of NFTs and a significant increase in cortical and hippocampal neurons in the rTg(tauP301L)4510 mouse model. A significant increase in the levels of the PP2A protein, implicated in tau phosphorylation events, in PBT2 treated animals suggest that the drug may directly act upon biochemical pathways which lead to NFT formation as well as any potential interaction with tau itself, the company said. | |
|
News For PRAN From The Last 14 Days Check below for free stories on PRAN the last two weeks. |
|
|
| There are no results for PRAN |
|
|
|
|
|
|
